Category: Joint ventures/collaborations
-
FDA, Emulate to Test Organs-on-Chips for Drug Toxins
A joint venture between Food and Drug Administration and a developer of chip devices simulating human organs, is evaluating the chips as a way to test new drugs for toxic effects.
-
Antibody Shows Promise Against Marburg Virus Infections
Tests with lab animals show an experimental synthetic antibody protects against deadly Marburg and Ravn viruses as long as 5 days following infections.
-
Prodrugs Designed to Better Target Cancer Therapies
A delivery mechanism is being developed to package cancer drugs in a nanoscale precursor state that reacts only in tumor regions, to protect against adverse effects.
-
CARB-X Commits $48M for Antibiotic Resistance R&D
A public-private partnership is spending $48 million in grants to biotechnology companies for research on treatments and diagnostics to counter antibiotic resistance, with half of that amount distributed immediately.
-
Climate-Resistant Oilseed Crop Plant Developed
An academic-industry team developed a new crop plant variety that produces cooking oil like rapeseed or canola, but in a warmer and dryer climate.
-
Regeneron to Sequence 500K UK Biobank Genomes
A biotech company and health database center are partnering with drug maker GlaxoSmithKline to produce genomic data on 500,000 individuals for drug discovery.
-
Inhaled Drug Shown Feasible for Postpartum Bleeding
Results from a clinical trial show a dry-powder inhaled form of the drug oxytocin works in the body much like the injected form, given to prevent postpartum hemorrhage, excessive bleeding in some women after childbirth.
-
Heart Assoc, Amazon Partner on Precision Medicine Data
American Heart Association and Amazon Web Services are collecting data from researchers to advance precision medicine in cardiovascular diseases and stroke.
-
Allergan to Option Gene Editing for Eye Diseases
International drug maker Allergan is gaining access to treatments for inherited eye diseases being developed by Editas Medicine, a spin-off enterprise from MIT and Harvard.
-
Messenger RNA Engineered to Produce Antibodies
Academic and industry researchers demonstrated production of therapeutic antibodies inside cells of lab mice, offering a simpler and lower-cost alternative to monoclonal antibodies.